Table 1 Demographic, Clinical, Anthropomorphic and Biochemical Data of Buprenorphine (n = 26)- and Methadone (n = 32)-treated Subjects.

From: Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone

Variable

Buprenorphine

Methadone

Student’s t-test

t-value

p

Demographic and clinical data

Age (year)

39.92 (9.92)

41.17 (7.92)

−0.53

0.60

Education (year)

12.54 (1.36)

12.28 (0.99)

0.83

0.41

ASI (composite score; range 0–1.00)

0.30 (0.14)

0.27 (0.11)

1.00

0.32

Total craving (score)

−5.13 (13.70)

−6.46 (10.59)

0.40

0.69

Total BDI (score)

20.52 (16.34)

21.07 (13.98)

−0.13

0.89

Smoking (cigarette/day)

8.44 (7.87)

9.57 (7.58)

−0.51

0.61

Daily physical activity (0–5)

1.54 (1.48)

1.78 (1.26)

0.68

0.50

MAT

Dose (mg)

14.85 (4.81)

78.34 (37.99)

n/a

n/a

Duration (day)

694.80 (809.57)

937.50 (862.98)

−1.08

0.28

DDD (#)

1272.00 (1445.12)

3036.41 (3560.73)

−2.33

0.02

Anthropometrics

BMI (kg/m2)

29.21 (4.36)

30.32 (7.44)

−0.68

0.50

Body fat mass (kg)

57.77 (17.00)

56.00 (29.42)

0.80

0.26

Body fat mass (%)

32 (8.10)

29 (11.27)

0.83

0.41

Fat free mass (kg)

123.33 (15.22)

128.22 (23.63)

−0.87

0.39

Fat free mass (%)

68.45 (8.10)

70.75 (11.27)

−0.83

0.41

Total body water (kg)

42.05 (5.13)

43.65 (7.69)

−0.87

0.39

Total body water (%)

51.45 (6.03)

53.19 (8.57)

−0.83

0.41

Metabolic syndrome

Waist (cm)

101.06 (12.49)

102.98 (5.3)

−0.49

0.62

Triglycerides (mg/dL)

113.60 (68.72)

133.72 (62.80)

−1.12

0.27

HDL (mg/dL)

49.39 (15.46)

38.97 (9.98)

3.00

0.004

Systolic BP (mmHg)

119.96 (11.04)

131.25 (21.66)

−2.38

0.02

Diastolic BP (mmHg)

75.15 (9.99)

81.18 (13.53)

−1.85

0.07

Glucosebaseline (mg/dL)

90.78 (13.62)

90.23 (21.78)

0.11

0.91

Metabolic indices

Glucose120 min (mg/dL)

98.56 (28.24)

108.81 (38.95)

−1.07

0.29

Insulinbaseline (mIU/L)

11.67 (9.16)

23.91 (53.02)

−1.23

0.22

Insulin120 min (mIU/L)

27.82 (22.17)

40.17 (34.16)

−1.52

0.14

Triglycerides/HDL

2.76 (2.50)

3.87 (2.41)

−1.68

0.10

Total cholesterol (mg/dL)

173.27 (40.00)

165.04 (42.79)

0.74

0.47

LDL (mg/dL)

108.42 (35.84)

104.61 (44.11)

0.39

0.70

Hemoglobin A1C (%)

5.38 (0.44)

5.61 (0.65)

−1.51

0.14

HOMA-IR (pmol*mmol/L2)

2.69 (2.31)

7.10 (17.6)

−1.24

0.22

HOMA-β (%)

21.93 (704.36)

246.38 (297.98)

−1.47

0.15

MAP (mmHg)

90.09 (9.04)

97.87 (14.85)

−2.30

0.03

GlucoseAUC * InsulinAUC

64727891 (39803279)

114114932 (110516922)

−2.10

0.04

STT

Taste_0.05 M (mm)

−0.30 (1.32)

−0.25 (1.73)

−0.12

0.91

Taste_0.1 M (mm)

0.23 (1.04)

−0.12 (1.44)

0.95

0.34

Taste_0.21 M (mm)

1.47 (1.57)

1.12 (1.42)

0.81

0.42

Taste_0.42 M (mm)

2.82 (0.98)

2.86 (1.73)

−0.08

0.94

Taste_0.83 M (mm)

3.88 (1.12)

4.28 (0.87)

−1.36

0.18

Like_0.05 M (mm)

−0.32 (1.84)

−0.62 (2.36)

0.49

0.62

Like_0.1 M (mm)

0.00 (1.89)

−0.26 (2.29)

0.33

0.67

Like_0.21 M (mm)

0.54 (1.61)

0.54 (2.33)

0.39

0.70

Like_0.42 M (mm)

1.11 (2.01)

0.96 (2.60)

0.20

0.84

Like_0.83 M (mm)

1.65 (2.25)

1.01 (2.46)

0.70

0.49

 

Fisher’s exact test

 

p

Ratios

Gender (F/M)

13/13

9/23

 

0.11

Race (W/B)

24/2

29/3

 

1.00

Marital status (S/P)

19/7

29/3

 

0.10

Employment (Y/N)

5/21

7/25

 

1.00

Metabolic syndrome (Y/N)

5/21

18/14

 

0.007

  1. Data are presented as mean (SD) or ratios.
  2. ASI, Addiction Severity Index; AUC, area under the curve; BMI, Body mass index; DDD, defined daily dose; HDL, High-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; HOMA-β, homeostasis model assessment-beta cell function; LDL, low-density lipoproteins; Like_0.05 M, lowest sucrose solution concentration liking self-rating; M, Molar; MAP, mean arterial pressure; MAT, Medication-assisted treatment; STT, sweet taste test; Taste_0.05 M, lowest sucrose solution concentration taste self-rating.
Back to article page